The authorized function is the ceiling
What a regulator has authorized an ingredient to do is a separate question from what studies suggest it might do. The narrower of the two governs the label.
Ingredient Assessments
What an ingredient actually supports — and what it does not.
Candidate-ingredient assessments recording the authorized function, what the evidence supports, what it does not, and the constraints attached to each.
How to read an assessment
Three lists, and the order matters.
An assessment exists so a candidate ingredient's real evidence and regulatory position are on record before it reaches a formulation brief — including where the honest answer is that the market implies more than the literature supports.
Evidence is read by species and dose
A result in calves is not a result in dogs, and a result at one inclusion level is not a result at another. Assessments keep those boundaries explicit.
Constraints travel with the ingredient
Sourcing risk, antagonism with other actives and particle-size specifications are development decisions, not footnotes.
Development inputs, not claims
Nothing on this page is a finished formula, an approved claim or a statement of product availability. Assessments inform development work; a marketed claim still requires the finished formula and its own substantiation record.
Ingredient assessment
Clinoptilolite (sedimentary origin)
CAS 12173-10-3 · EU additive 1g568 · specify clinoptilolite, never “zeolite”
Authorized function
Technological additive only — pellet binder and anticaking agent. The EU authorises it at up to 1% of complete feed under Regulation (EU) 2026/167. The US position rests on a GRAS notice for anticaking use to which FDA raised no questions, which is not the same thing as an authorisation; no US authority has set a clinoptilolite-specific safety ceiling. No jurisdiction authorises a digestive, immune or toxin-binding function.
A microporous aluminosilicate whose framework carries a net negative charge balanced by exchangeable cations. It works by cation exchange and size-selective adsorption rather than absorption — it is essentially not absorbed and leaves in the faeces — and its defining property is a high selectivity for ammonium. That ammonia affinity is the best-established thing about it and the mechanism behind most of its credible effects. The evidence then separates sharply by species and function: genuinely promising in the neonatal-calf colostrum window, established for ruminal ammonia, close to absent in dogs. Its authorization in both the EU and US covers a manufacturing function, so what the science supports and what a label may say are two different questions.
What the evidence supports 5
- Colostral immunoglobulin absorption in newborn calves, given within the first 24 hours at low inclusion. One controlled trial (n=60) found higher serum IgG and higher apparent efficiency of absorption with a clinoptilolite suspension versus colostrum alone; a second (n=18) found γ-globulin — a proxy for IgG rather than a direct measure — above control at the 0.5% dose. Both point to enhanced absorption rather than interference, and both come from closely related research groups. Timing is intrinsic: the window closes as the gut does.
- Ruminal ammonia reduction in cattle at fine grind (~30 µm); coarse material did not produce the effect.
- Tolerance in neonatal calves at up to 2% of milk replacer for 28 days, with no gross lesions at necropsy.
- Trace-mineral safety in dairy cattle at 1.25–2.5% across a full lactation, with no adverse effect on serum copper, zinc or iron.
- Anticaking and pellet-binding performance at authorized inclusion levels — the only function either jurisdiction has actually authorized.
What it does not support 5
- Canine digestive or stool-quality claims. The only canine trial of clinoptilolite used ten dogs, was not blinded, and appeared in a journal not indexed in PubMed. The one controlled canine microbiota study used a different zeolite entirely, with clinoptilolite absent from the formulation.
- Diarrhoea treatment in any species. The most rigorous trial against a diarrhoea endpoint — double-blind, placebo-controlled, twelve weeks — missed its primary endpoint.
- Toxin-binding or detoxification claims. US regulators hold that binding claims for aluminosilicates are not generally recognised as safe and require an approved food additive petition.
- Growth or performance benefit in calves; two controlled trials found no difference.
- Milk-fever prevention. That effect belongs to synthetic zeolite A, a different, acid-unstable, calcium-binding material — the literature does not transfer.
Cautions and constraints 9
- The colostrum benefit is dose-critical, not linear. Roughly 0.5% of the colostrum meal outperformed 2% in the only head-to-head trial, and above about 0.5–1.0 g/kg bodyweight per day the reported effect turns toward inhibition. More is not better here, and any product would need its own passive-transfer verification rather than inherited data.
- The supporting calf trials are small (n=60 and n=18), unblinded, and clustered in one research group, with no clinical endpoints recorded and no established mechanism. That is enough to justify development work; it is not enough to support a marketing claim.
- Immune and immunoglobulin claims are the sharpest regulatory line in this category. In the US, a product presented as acting on immunity falls under veterinary biologics licensing, not feed registration — so the science and the permitted label language must be tracked separately.
- Erionite contamination is the most serious sourcing risk, and it is controlled at the deposit rather than in processing — the two minerals are too close in density to separate, and in the tuff deposits that supply commercial clinoptilolite erionite sits intergrown in the matrix. It is a Group 1 human carcinogen, is routinely misidentified as offretite, and is not covered by an asbestos-free certificate because no zeolite appears on the regulatory asbestos list. Qualification therefore means naming the mine and horizon, then verifying by transmission electron microscopy with structure and chemistry read together on each candidate fibre.
- Antagonism is documented: reduced monensin, tocopherol and riboflavin utilisation at 2% inclusion, and reduced phosphorus retention in swine. Do not co-formulate with ionophores or fat-soluble vitamin packs without validating recovery.
- Heavy-metal load varies roughly fortyfold between equally authorized deposits, so deposit identity — not the mineral name — governs the specification.
- Specify clinoptilolite by name and CAS number, never “zeolite.” The zeolite family includes chabazite, phillipsite, mordenite, analcime and synthetic zeolite A, none of which share clinoptilolite's regulatory status or safety record — synthetic zeolite A is acid-unstable, binds dietary calcium and releases aluminium into circulation, while clinoptilolite's higher silica content keeps it acid-stable. Published work on other family members does not transfer, in either direction.
- Sedimentary and volcanic origin are separate regulatory materials; modified, acid-activated and micronized forms fall outside both authorizations.
- Particle size is a functional specification, not a detail, and the optimum conflicts by purpose: fine (~30 µm) reduced ruminal ammonia where 400 µm did not, but coarse material outperformed fine for manure ammonia emissions. Decide the intended function before setting the grind.
Sources behind this assessment
Each record states what it supports and what it cannot establish. Read both lines.
6 sources · 2026 back to 2008
Commission Implementing Regulation (EU) 2026/167 renewing the authorisation of clinoptilolite of sedimentary origin
European Commission
Scope. The operative EU authorisation: additive 1g568, technological additives, functional groups binders and anticaking agents, all animal species, maximum 10,000 mg/kg complete feed.
Supports. Defines exactly what clinoptilolite is authorised to do and at what inclusion, together with the composition specification (≥80% clinoptilolite, ≤20% clay minerals free of fibres and quartz) and mandatory worker-protection provisions.
Does not establish. Does not authorise any zootechnical, gut-health, detoxification or mycotoxin-binding function — those are separate functional groups that clinoptilolite does not hold.
Primary source ↗Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: randomized controlled trial
World Journal of Gastroenterology
Scope. Double-blind, placebo-controlled randomised trial of purified clinoptilolite-tuff over twelve weeks against a diarrhoea and symptom endpoint. Human study, included as the fairest available check on digestive positioning for this ingredient.
Supports. The most rigorous test of clinoptilolite against a diarrhoea endpoint in any species, and therefore the fairest available check on digestive-support positioning.
Does not establish. Does not support a digestive-symptom claim — the trial missed its primary endpoint, with responder rates no better than placebo; it is also a human study and does not transfer directly to any animal species.
Primary source ↗Serum protein electrophoretic pattern in neonatal calves treated with clinoptilolite
Molecules
Scope. 18 calves in three groups — colostrum alone, colostrum plus 0.5% clinoptilolite, colostrum plus 2% — dosed within two hours of birth and again at 12 and 24 hours.
Supports. The only head-to-head dose comparison in the colostrum window: at 30 hours the 0.5% group showed γ-globulin markedly above control, and the authors conclude the lower dose was the more effective of the two.
Does not establish. Does not measure IgG directly (γ-globulin is a proxy), uses six calves per arm, records no clinical endpoint, and shows the higher 2% dose performing worse than 0.5% — the effect is dose-critical, not linear.
Primary source ↗IARC Monographs Volume 100C: Erionite
International Agency for Research on Cancer
Scope. Authoritative carcinogenicity evaluation of the fibrous zeolite erionite and its natural occurrence alongside other zeolite minerals.
Supports. Establishes why an explicit erionite specification is mandatory when sourcing natural zeolite: erionite is carcinogenic to humans, causes mesothelioma, and is normally associated with other zeolites including clinoptilolite.
Does not establish. Does not provide an occupational exposure limit, a validated feed-grade screening method, or any safe threshold — so a specification must state its own method and limit of detection.
Primary source ↗Apparent efficiency of immunoglobulin absorption in newborn calves orally treated with zeolite
Acta Veterinaria
Scope. 60 Holstein calves in four groups, fed colostrum at two volumes with or without a 25% clinoptilolite suspension, measuring serum IgG and apparent efficiency of absorption.
Supports. The largest trial addressing clinoptilolite and colostral immunoglobulin directly: serum IgG at six hours was significantly higher with zeolite at the lower colostrum volume, and apparent efficiency of absorption was highest in that group — the mineral enhanced rather than impaired absorption.
Does not establish. Does not establish a mechanism, was not blinded, records no clinical outcomes such as morbidity or scours, and comes from a single research group.
Primary source ↗Clinical observations, biochemical data and postmortem findings in young dairy calves fed zeolite clinoptilolite with milk replacer
American Journal of Veterinary Research
Scope. 26 Holstein calves fed milk replacer with 0%, 0.5% or 2% clinoptilolite twice daily for 28 days, all necropsied.
Supports. The best tolerance dataset in neonatal calves — no gross lesions attributable to treatment at necropsy, and no adverse haematology or biochemistry.
Does not establish. Does not show any benefit; it was designed as a safety study, found no difference in bodyweight or average daily gain, and reported an unexplained increase in jejunal mucosal eosinophils in treated calves.
Primary source ↗Ingredient assessment
L-theanine
γ-glutamylethylamide · CAS 3081-61-6 · Suntheanine · Anxitane (branded canine tablet)
Authorized function
None. No US or EU authority authorises L-theanine for a calming, behavioural or nervous-system function in dog food. There is no dietary-supplement category for animals — DSHEA does not extend to them — so the only lawful positions are a defined feed ingredient used for nutritive value, or an approved new animal drug. A calm or focus claim is neither: it names a non-nutritive effect on structure or function, which is the statutory drug test, and it points at anxiety, an indication for which FDA-approved canine drugs already exist.
The most-printed calming ingredient in the pet category and one of the least-evidenced. Its canine literature is real but tiny, and it is invisible to PubMed — a search there returns exactly one record, and that record is a cat study. The canine work sits in the Journal of Veterinary Behavior, unindexed for those volumes: one laboratory-model paper, one open-label study in 26 client-owned dogs, and two conference abstracts. Not one is a blinded, placebo-controlled trial in client-owned dogs. The open-label study lost 8 of its 26 dogs and its outcome was an owner-scored anxiety rating — precisely the measure a 2023 canine review identifies as indistinguishable from caregiver placebo. Nothing in any species tests focus, attention or cognition in dogs, so the focus half of a calm-focus claim has no referent at all.
What the evidence supports 2
- Nothing at the standard a claim requires. The strongest canine finding is a reduction in owner-reported anxiety and faster return to baseline after a storm, in an open-label study with no placebo arm and 31% attrition — a design that cannot separate ingredient from expectation.
- Tolerance at the doses used in dogs is unremarkable: roughly 50 mg/day under 10 kg, 100 mg/day at 10–25 kg and 200 mg/day above 25 kg, without reported adverse events. That supports safety at those levels and nothing else.
What it does not support 5
- Any calm, calming, anxiolytic or stress-reduction claim in dogs. No blinded placebo-controlled canine trial exists in the literature located.
- Any focus, attention or cognitive claim in dogs. No canine study has measured a focus endpoint — this limb is unsupported by even weak evidence.
- Transfer from the feline evidence. The one PubMed-indexed companion-animal study is in 33 cats, open-label with no control arm.
- Transfer from human green-tea and theanine literature, conducted at human doses against self-reported psychological scales dogs cannot produce.
- Monotherapy positioning. A 2023 canine review concludes most nutraceuticals will likely provide insufficient relief as monotherapy for noise fears, and that the effect of the majority does not exceed caregiver placebo.
Cautions and constraints 5
- The evidence gap here is invisible to a normal literature check. PubMed returns one cat study, so a search that stops there reports zero canine evidence; Crossref returns four canine records, two of which are short conference abstracts that look like papers in a citation list. Any substantiation file must state which it relies on and what design each actually had.
- The canine laboratory-model paper is paywalled and was produced with manufacturer involvement. Its sample size and effect size could not be independently verified, so it must not be cited as support until the full text has been read.
- Owner-reported anxiety scores are the outcome in the only client-owned canine study, and they are the measure most exposed to caregiver placebo. That is the specific reason the canine review declines to endorse the category.
- Calm and focus are two claims, not one. They require separate substantiation, and the focus limb has no canine evidence of any design.
- L-theanine has no AAFCO ingredient definition establishing a calming function. Its lawful use rests on being a suitable food substance used for nutritive value; the moment a label explains why it is there in behavioural terms, the intended use changes and the product's regulatory class changes with it.
Sources behind this assessment
Each record states what it supports and what it cannot establish. Read both lines.
7 sources · 2025 back to 1938
Behavior problems of dogs
MSD Veterinary Manual
Scope. Professional reference on canine fear, anxiety, separation anxiety and noise aversion — diagnosis, medical rule-outs, behaviour modification and pharmacotherapy.
Supports. Establishes why calm language is a regulatory hazard rather than a marketing choice: canine anxiety is a diagnosable clinical disorder requiring medical rule-outs, and fluoxetine and clomipramine are FDA-approved drugs for canine separation anxiety — an approved-drug indication a food cannot claim into.
Does not establish. Does not endorse any nutritional product; it states that evidence of the effectiveness of natural products in dogs is somewhat limited and positions them as adjunctive to behaviour modification, never as treatment.
Primary source ↗Therapy and prevention of noise fears in dogs — a review of the current evidence for practitioners
Animals / University of Bern
Scope. Review of the evidence for every major intervention class in canine noise fear — environmental management, counterconditioning, desensitisation, anxiolytic medication, nutraceuticals, herbals, pheromones and homeopathy.
Supports. The single best summary of where calm-behaviour nutrition actually sits: it places nutraceuticals below medication and below training, and identifies caregiver placebo as the dominant explanation for reported effects.
Does not establish. Does not test any ingredient itself, and states the opposite of a calm claim — that the effect of the majority of nutraceuticals in use does not exceed that of a caregiver placebo effect, and that most will likely provide insufficient relief as monotherapy for noise fears.
Primary source ↗Dietary strategies for relieving stress in pet dogs and cats
Antioxidants (Basel)
Scope. Tabulated review of dietary compounds studied against stress endpoints in dogs and cats, listing species, dose and reported outcome for each — including L-theanine, alpha-casozepine and L-tryptophan.
Supports. Establishes the boundary of the field by enumeration: it is the most complete catalogue of what has actually been fed to dogs for stress, with doses attached.
Does not establish. Does not appraise risk of bias, dose-response or study quality, and contains no entry for magnesium or chamomile in dogs — the absence in a review built to find such studies is itself the finding.
Primary source ↗FDA's regulation of pet food
U.S. Food and Drug Administration, Center for Veterinary Medicine
Scope. How the food/drug line applies to pet food, pre-market review, food additives and GRAS, and the inapplicability of DSHEA to animals.
Supports. Confirms animal food needs no FDA pre-market review unless a food additive, but must be safe, sanitary and truthfully labeled; and that there is no dietary-supplement category for animals.
Does not establish. Does not establish that a product exempt from pre-market review is lawfully claimed — it addresses approval status, not claim substantiation.
Primary source ↗Effect of l-theanine tablets in reducing stress-related emotional signs in cats: an open-label field study
Irish Veterinary Journal
Scope. Feline study, included as the fairest available off-species check on L-theanine positioning. Open-label field study in 33 cats with stress-related emotional signs, scoring 20 behavioural parameters over 30 days. The only L-theanine companion-animal study indexed in PubMed.
Supports. Reports that all 20 median parameter scores fell significantly by day 30, with most cats improving within two weeks.
Does not establish. Does not transfer to dogs, and does not establish an ingredient effect in any species: it is open-label with no placebo or control arm, so within-subject improvement cannot be separated from regression to the mean or caregiver expectation.
Primary source ↗An open-label prospective study of the use of l-theanine (Anxitane) in storm-sensitive client-owned dogs
Journal of Veterinary Behavior
Scope. Open-label prospective study in 26 client-owned storm-sensitive dogs, measuring owner-reported global anxiety score and time to return to baseline after a storm. The only full-length canine L-theanine paper in client-owned dogs.
Supports. Reports a reduction in owner-scored anxiety and faster return to baseline — the entire real-world basis for canine L-theanine positioning.
Does not establish. Does not control for placebo at all — it is open-label with no blinded comparator, outcomes are owner-reported, and 8 of 26 dogs dropped out prematurely, which the 2023 noise-fear review flags as creating potential bias in the remaining analysed subjects.
Primary source ↗21 U.S.C. § 321 — Definitions of food and drug
Federal Food, Drug, and Cosmetic Act (US Code)
Scope. Statutory definitions of food as articles used for food or drink for man or other animals, and drug as articles intended to diagnose, cure, mitigate, treat or prevent disease, or (other than food) to affect structure or function.
Supports. Establishes that the food/drug line is drawn by intended use rather than by ingredient — the same substance becomes a drug the moment a disease or non-nutritive structure-function intent is expressed.
Does not establish. Does not establish that any particular marketing sentence is lawful; it supplies the test, not its application.
Primary source ↗Ingredient assessment
Chamomile (Matricaria)
Matricaria chamomilla L. · Matricaria recutita · German chamomile · apigenin and α-bisabolol are the cited actives · distinct from Roman chamomile (Chamaemelum nobile)
Authorized function
None for behaviour. Botanicals in US animal food are lawful only as flavouring or as an ingredient used for nutritive value; there is no authorised nervous-system or relaxation function in any jurisdiction. A “supports relaxation and nervous system” claim names a body system explicitly, which is the clearest form of a structure/function drug claim under the statutory definition, and there is no dietary-supplement category for animals to fall back on.
The weakest ingredient in the calming set, and the only one with literally zero canine behavioural evidence. A PubMed search for chamomile and dogs returns nine records in total: topical dermatology, otitis externa, antiviral activity, scent-detection training, corneal healing, bisabolol toxicity and a 1988 cardiac-electrophysiology study. Not one concerns behaviour, anxiety or relaxation. A 2023 peer-reviewed review built specifically to catalogue dietary compounds fed to dogs and cats for stress contains no chamomile entry at all. The ingredient's entire reputation comes from human generalised-anxiety-disorder trials — and even there the best long-term randomised trial missed its primary endpoint. It is also the ingredient most likely to be assumed safe: an Asteraceae botanical with documented cross-reactivity potential, whose canine literature is about putting it on dogs rather than in them.
What the evidence supports 1
- Nothing in dogs, for any behavioural or nervous-system outcome. The canine literature does not address the question.
What it does not support 5
- Any relaxation, calming or nervous-system claim in dogs. No canine study of any design has tested it — a complete absence, not a weak signal.
- Transfer from the human generalised-anxiety-disorder trials, which recruited diagnosed human patients at 1,500 mg/day of a standardised oral extract, and whose best long-term trial found no significant difference in time to relapse (HR 0.52, 95% CI 0.20–1.33, P = 0.16).
- Transfer from the canine topical dermatology and otitis literature, which concerns antimicrobial and anti-inflammatory activity applied to skin and ear, not ingestion or behaviour.
- Any inference from aromatherapy studies. Most human chamomile anxiety work is inhalation aromatherapy — an exposure route and outcome measure with no canine equivalent.
- Equivalence between preparations. Whole flower, aqueous infusion, standardised apigenin extract and essential oil are different materials with different actives at different concentrations; the human trial data attaches to one standardised oral extract only.
Cautions and constraints 5
- This is the sharpest claim-wording hazard in the calming set. “Supports relaxation and nervous system” names an organ system in terms, which is the textbook structure/function drug claim — more exposed than a vaguer calm phrase, not less.
- Chamomile is an Asteraceae (composite) botanical, the family that includes ragweed. Sensitisation and cross-reactivity are a documented concern in humans, and the canine data needed to characterise that risk does not exist.
- Roman chamomile (Chamaemelum nobile) and German chamomile (Matricaria chamomilla) are different plants with different constituent profiles. Specify the binomial and plant part; the human evidence attaches only to Matricaria.
- Essential oil is a separate material from the herb or extract and carries its own toxicity profile in companion animals. Do not let a herb-level rationale silently authorise an oil-level inclusion.
- Botanical identity, adulteration and pesticide residue are live supply-chain risks for a bulk flower ingredient. Specify binomial, plant part, extraction solvent, marker compound and assay before any inclusion.
Sources behind this assessment
Each record states what it supports and what it cannot establish. Read both lines.
7 sources · 2025 back to 1938
Reading labels — nutritional adequacy statement formats
Association of American Feed Control Officials
Scope. Required label elements, the standardized nutritional adequacy statement formats, and what constitutes misbranding.
Supports. Gives the exact prescribed wording for each substantiation route and confirms that an incorrect adequacy statement, or a disease claim without an approved drug, is misbranding.
Does not establish. Does not carry force of law on its own — AAFCO models bind only where a state has adopted them, and AAFCO approves, certifies and endorses nothing.
Primary source ↗Behavior problems of dogs
MSD Veterinary Manual
Scope. Professional reference on canine fear, anxiety, separation anxiety and noise aversion — diagnosis, medical rule-outs, behaviour modification and pharmacotherapy.
Supports. Establishes why calm language is a regulatory hazard rather than a marketing choice: canine anxiety is a diagnosable clinical disorder requiring medical rule-outs, and fluoxetine and clomipramine are FDA-approved drugs for canine separation anxiety — an approved-drug indication a food cannot claim into.
Does not establish. Does not endorse any nutritional product; it states that evidence of the effectiveness of natural products in dogs is somewhat limited and positions them as adjunctive to behaviour modification, never as treatment.
Primary source ↗Therapy and prevention of noise fears in dogs — a review of the current evidence for practitioners
Animals / University of Bern
Scope. Review of the evidence for every major intervention class in canine noise fear — environmental management, counterconditioning, desensitisation, anxiolytic medication, nutraceuticals, herbals, pheromones and homeopathy.
Supports. The single best summary of where calm-behaviour nutrition actually sits: it places nutraceuticals below medication and below training, and identifies caregiver placebo as the dominant explanation for reported effects.
Does not establish. Does not test any ingredient itself, and states the opposite of a calm claim — that the effect of the majority of nutraceuticals in use does not exceed that of a caregiver placebo effect, and that most will likely provide insufficient relief as monotherapy for noise fears.
Primary source ↗Dietary strategies for relieving stress in pet dogs and cats
Antioxidants (Basel)
Scope. Tabulated review of dietary compounds studied against stress endpoints in dogs and cats, listing species, dose and reported outcome for each — including L-theanine, alpha-casozepine and L-tryptophan.
Supports. Establishes the boundary of the field by enumeration: it is the most complete catalogue of what has actually been fed to dogs for stress, with doses attached.
Does not establish. Does not appraise risk of bias, dose-response or study quality, and contains no entry for magnesium or chamomile in dogs — the absence in a review built to find such studies is itself the finding.
Primary source ↗FDA's regulation of pet food
U.S. Food and Drug Administration, Center for Veterinary Medicine
Scope. How the food/drug line applies to pet food, pre-market review, food additives and GRAS, and the inapplicability of DSHEA to animals.
Supports. Confirms animal food needs no FDA pre-market review unless a food additive, but must be safe, sanitary and truthfully labeled; and that there is no dietary-supplement category for animals.
Does not establish. Does not establish that a product exempt from pre-market review is lawfully claimed — it addresses approval status, not claim substantiation.
Primary source ↗Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial
Phytomedicine / University of Pennsylvania
Scope. Human study, included as the fairest available check on chamomile positioning. Twelve weeks open-label chamomile extract at 1,500 mg/day followed by 26 weeks double-blind placebo-substitution in 179 enrolled adults, of whom 93 responders were randomised.
Supports. The most rigorous test chamomile has against an anxiety endpoint in any species, and the reason the ingredient has a scientific reputation at all.
Does not establish. Does not establish efficacy even in humans — the primary endpoint, time to relapse, was not significant (HR 0.52, 95% CI 0.20–1.33, P = 0.16); it is a human trial in diagnosed generalized anxiety disorder at a standardised oral extract dose, and nothing in it transfers to dogs.
Primary source ↗21 U.S.C. § 321 — Definitions of food and drug
Federal Food, Drug, and Cosmetic Act (US Code)
Scope. Statutory definitions of food as articles used for food or drink for man or other animals, and drug as articles intended to diagnose, cure, mitigate, treat or prevent disease, or (other than food) to affect structure or function.
Supports. Establishes that the food/drug line is drawn by intended use rather than by ingredient — the same substance becomes a drug the moment a disease or non-nutritive structure-function intent is expressed.
Does not establish. Does not establish that any particular marketing sentence is lawful; it supplies the test, not its application.
Primary source ↗Ingredient assessment
Magnesium (for behaviour)
Mg · assessed here for behavioural positioning only — magnesium as an essential mineral is a separate, settled question with an NRC requirement · sources include magnesium oxide, citrate, sulfate, chelates
Authorized function
Magnesium is an essential nutrient with an established NRC requirement for dogs, and may be declared and supplied as such. That authorisation is nutritional and nothing more. No jurisdiction authorises a behavioural or calming function, and attaching “supports calm behavior” to it converts a lawful nutrient declaration into a non-nutritive structure/function claim about the nervous system — the statutory drug test — while pointing at anxiety, a diagnosable disease with FDA-approved canine drugs.
The cleanest absence in the portfolio, and the one most likely to be mistaken for evidence — because magnesium genuinely is an essential nutrient with a real requirement and a real role in neuromuscular function. None of that is behavioural evidence. No controlled trial has ever tested magnesium supplementation against an anxiety or calm-behaviour endpoint in dogs, confirmed across PubMed and Europe PMC and corroborated by a 2023 review of dietary stress strategies that contains no magnesium entry. Exactly one canine study connects magnesium to stress at all: an observational pilot in guide-dog candidates showing serum Mg2+ falling in winter, in novice trainees and after treadmill exercise. It is a measurement study in 4 to 14 dogs per group with no behavioural outcome and no supplementation arm, and its closing line — that supplementation should be considered — is author speculation. That sentence is the entire foundation of magnesium's calming reputation in the pet category, and it is not a finding.
What the evidence supports 2
- Magnesium as an essential nutrient at NRC-defined intakes. This supports a nutrient declaration and a guaranteed analysis, and supports no behavioural inference whatsoever.
- An observational association only: serum Mg2+ in dogs varies with season, training stage and physical exertion. An association in one direction, in a pilot, with no outcome measured.
What it does not support 4
- Any calm-behaviour, anxiety or stress-reduction claim in dogs. No canine supplementation trial exists against any behavioural endpoint — a total absence, verified independently in two databases.
- The inference that low serum magnesium under stress means supplementation improves behaviour. The pilot measured a correlate and tested no intervention; causation is unestablished and the outcome was never behavioural.
- Transfer from the human magnesium-anxiety literature, which its own systematic reviewers describe as poor quality — benefit in only 4 of 8 anxious samples, every sample already anxiety-vulnerable, no validated stress measure used.
- Any claim that a complete and balanced diet needs supplemental magnesium for behaviour. A diet meeting the profile already supplies the requirement; magnesium above requirement has no demonstrated behavioural effect and is not a nutrient contribution.
Cautions and constraints 5
- This is where the nutrient/claim distinction is easiest to blur and most dangerous to blur. The nutrient is lawful and real; the behavioural claim is neither. Keep them in separate columns and never let the requirement justify the claim.
- Do not cite the guide-dog serum pilot as support. Its concluding recommendation is speculation unsupported by its own data, and citing it would fail the reasonable-basis test — a claim advertised as study-supported binds the firm to that level of support.
- Magnesium above requirement is not benign. Excess is a laxative at the gut and is renally cleared, so any behaviourally motivated overage raises loose-stool risk and is inadvisable in dogs with reduced renal function.
- Source form changes bioavailability and gut tolerance substantially (oxide versus citrate versus chelate). If magnesium is included, the specification must name the salt, not the element.
- Magnesium interacts with the calcium and phosphorus balance of the whole diet. A behavioural inclusion decided outside the mineral premix can disturb ratios that were set to meet the profile.
Sources behind this assessment
Each record states what it supports and what it cannot establish. Read both lines.
7 sources · 2025 back to 1938
Behavior problems of dogs
MSD Veterinary Manual
Scope. Professional reference on canine fear, anxiety, separation anxiety and noise aversion — diagnosis, medical rule-outs, behaviour modification and pharmacotherapy.
Supports. Establishes why calm language is a regulatory hazard rather than a marketing choice: canine anxiety is a diagnosable clinical disorder requiring medical rule-outs, and fluoxetine and clomipramine are FDA-approved drugs for canine separation anxiety — an approved-drug indication a food cannot claim into.
Does not establish. Does not endorse any nutritional product; it states that evidence of the effectiveness of natural products in dogs is somewhat limited and positions them as adjunctive to behaviour modification, never as treatment.
Primary source ↗Dietary strategies for relieving stress in pet dogs and cats
Antioxidants (Basel)
Scope. Tabulated review of dietary compounds studied against stress endpoints in dogs and cats, listing species, dose and reported outcome for each — including L-theanine, alpha-casozepine and L-tryptophan.
Supports. Establishes the boundary of the field by enumeration: it is the most complete catalogue of what has actually been fed to dogs for stress, with doses attached.
Does not establish. Does not appraise risk of bias, dose-response or study quality, and contains no entry for magnesium or chamomile in dogs — the absence in a review built to find such studies is itself the finding.
Primary source ↗Analysis of serum magnesium ions in dogs exposed to external stress: a pilot study
Open Veterinary Journal
Scope. Observational pilot in guide-dog candidates and healthy adult dogs measuring serum Mg2+ across seasons, training stage and a treadmill forced-exercise challenge, 4–14 dogs per group.
Supports. The only canine study in the literature linking magnesium to stress at all: serum Mg2+ fell in winter, was markedly lower in novice than advanced trainees, and dropped significantly after forced treadmill exercise.
Does not establish. Does not test supplementation and measures no behavioural or anxiety outcome; its closing recommendation that supplementation should be considered is author speculation with no interventional data behind it and must not be cited as support for a calm claim.
Primary source ↗The effects of magnesium supplementation on subjective anxiety and stress — a systematic review
Nutrients / University of Leeds
Scope. Human evidence, included as the fairest available check on magnesium positioning. Systematic search across Medline, PsycINFO, Embase, CINAHL and Cochrane plus grey literature, including 18 human intervention studies.
Supports. The complete magnesium-anxiety evidence base in one place, and the honest ceiling on it: benefit was found in only 4 of 8 anxious samples and 4 of 7 premenstrual samples.
Does not establish. Does not establish efficacy in any species — the authors conclude the quality of the existing evidence is poor; every study recruited humans already vulnerable to anxiety, no study used a validated subjective stress measure, and many combined magnesium with other actives.
Primary source ↗Nutrient Requirements of Dogs and Cats
National Research Council / National Academies Press
Scope. Consensus requirements, adequate intakes and recommended allowances for every essential nutrient in dogs and cats, across life stages.
Supports. The quantitative floor and ceiling for formulating canine diets and complementary products.
Does not establish. Does not establish requirements, doses or efficacy for probiotics, prebiotics, postbiotics, glucosamine, collagen or any other non-essential ingredient.
Primary source ↗FTC policy statement regarding advertising substantiation
U.S. Federal Trade Commission
Scope. The prior-substantiation doctrine: advertisers must have a reasonable basis for objective claims before those claims are disseminated.
Supports. Establishes that lacking a reasonable basis is itself a deceptive act; that firms are held to reasonable implied readings; and that phrases such as “studies show” bind a firm to that advertised level of support.
Does not establish. Does not specify the evidence required for any particular claim — the reasonable basis is a sliding scale set by claim type, consequences of falsity and expert norms.
Primary source ↗21 U.S.C. § 321 — Definitions of food and drug
Federal Food, Drug, and Cosmetic Act (US Code)
Scope. Statutory definitions of food as articles used for food or drink for man or other animals, and drug as articles intended to diagnose, cure, mitigate, treat or prevent disease, or (other than food) to affect structure or function.
Supports. Establishes that the food/drug line is drawn by intended use rather than by ingredient — the same substance becomes a drug the moment a disease or non-nutritive structure-function intent is expressed.
Does not establish. Does not establish that any particular marketing sentence is lawful; it supplies the test, not its application.
Primary source ↗